Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
39 hedge funds and large institutions have $47.9M invested in Elevation Oncology in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
60.95% more ownership
Funds ownership: 68.62% → 129.57% (+61%)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
55% more capital invested
Capital invested by funds: $30.9M → $47.9M (+$17.1M)
44% more funds holding
Funds holding: 27 → 39 (+12)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.86M |
| 2 |
AC
Armistice Capital
New York
|
+$6.32M |
| 3 |
Millennium Management
New York
|
+$6.11M |
| 4 |
O
OrbiMed
New York
|
+$3.96M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.71M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.67M |
| 3 |
Walleye Capital
New York
|
-$872K |
| 4 |
Morgan Stanley
New York
|
-$382K |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$284K |
ELEV Hedge Fund Activity: Q2 2023 in Review
39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2023, worth a combined $47.9M — up 55% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ELEV positions and 6 closed out — a net gain of 12 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $6.86M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.71M sold.
- 39 institutional investors held Elevation Oncology (ELEV) as of Q2 2023, up from 27 in Q1 2023.
- Funds reported $47.9M of Elevation Oncology stock for Q2 2023, up 55% quarter-over-quarter.
- 18 funds opened new Elevation Oncology positions in Q2 2023 and 6 closed out, a net change of +12 holders.
- The largest Elevation Oncology buyer in Q2 2023 was Tang Capital Management, an estimated $6.86M added.
- The largest Elevation Oncology seller in Q2 2023 was Cormorant Asset Management, an estimated $3.71M sold.
Based on aggregated 13F filings for Q2 2023.